Tollefson GD - Search Results

1

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Basson BR, et al. Among authors: tollefson gd. J Clin Psychiatry. 2001 Apr;62(4):231-8. doi: 10.4088/jcp.v62n0404. J Clin Psychiatry. 2001. PMID: 11379836 Clinical Trial.

2

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.

Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD. Ascher-Svanum H, et al. Among authors: tollefson gd. J Psychopharmacol. 2005 Nov;19(6 Suppl):110-7. doi: 10.1177/0269881105058978. J Psychopharmacol. 2005. PMID: 16280344

3

Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.

Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ. Tollefson GD, et al. J Clin Psychopharmacol. 1999 Oct;19(5):435-43. doi: 10.1097/00004714-199910000-00007. J Clin Psychopharmacol. 1999. PMID: 10505585 Clinical Trial.

4

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Kinon BJ, et al. Among authors: tollefson gd. J Clin Psychiatry. 2001 Feb;62(2):92-100. J Clin Psychiatry. 2001. PMID: 11247108 Clinical Trial.

5

A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.

Beasley CM Jr, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, Alaka KJ, Bykowski D, Tollefson GD; Olanzapine Relapse Prevention Study Group. Beasley CM Jr, et al. Among authors: tollefson gd. J Clin Psychopharmacol. 2003 Dec;23(6):582-94. doi: 10.1097/01.jcp.0000095348.32154.ec. J Clin Psychopharmacol. 2003. PMID: 14624189 Clinical Trial.

6

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A. Feldman PD, et al. Among authors: tollefson gd. J Clin Psychiatry. 2003 Sep;64(9):998-1004. doi: 10.4088/jcp.v64n0904. J Clin Psychiatry. 2003. PMID: 14628974

7

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM. Tran PV, et al. Among authors: tollefson gd. J Clin Psychiatry. 1997 May;58(5):205-11. doi: 10.4088/jcp.v58n0505. J Clin Psychiatry. 1997. PMID: 9184614 Clinical Trial.

8

Safety of olanzapine.

Beasley CM Jr, Tollefson GD, Tran PV. Beasley CM Jr, et al. Among authors: tollefson gd. J Clin Psychiatry. 1997;58 Suppl 10:13-7. J Clin Psychiatry. 1997. PMID: 9265911

9

Olanzapine versus haloperidol treatment in first-episode psychosis.

Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Sanger TM, et al. Among authors: tollefson gd. Am J Psychiatry. 1999 Jan;156(1):79-87. doi: 10.1176/ajp.156.1.79. Am J Psychiatry. 1999. PMID: 9892301 Clinical Trial.

10

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Tollefson GD, et al. Am J Psychiatry. 1997 Apr;154(4):457-65. doi: 10.1176/ajp.154.4.457. Am J Psychiatry. 1997. PMID: 9090331 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

165 results

Search Page